[go: up one dir, main page]

AR065392A1 - Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio - Google Patents

Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio

Info

Publication number
AR065392A1
AR065392A1 ARP080100680A ARP080100680A AR065392A1 AR 065392 A1 AR065392 A1 AR 065392A1 AR P080100680 A ARP080100680 A AR P080100680A AR P080100680 A ARP080100680 A AR P080100680A AR 065392 A1 AR065392 A1 AR 065392A1
Authority
AR
Argentina
Prior art keywords
treatment
inhalation
disease
methods
respiratory state
Prior art date
Application number
ARP080100680A
Other languages
English (en)
Inventor
Supervia Jorge Beleta
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39247776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of AR065392A1 publication Critical patent/AR065392A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio en un paciente que necesite dicho tratamiento sin producir en dicho paciente efectos antimuscarínicos sistémicos, comprendiendo administrar a dicho paciente unacantidad eficaz de aclidinio.
ARP080100680A 2007-02-21 2008-02-20 Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio AR065392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90284307P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
AR065392A1 true AR065392A1 (es) 2009-06-03

Family

ID=39247776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100680A AR065392A1 (es) 2007-02-21 2008-02-20 Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio

Country Status (31)

Country Link
US (2) US20110243924A1 (es)
EP (1) EP2120936B1 (es)
JP (2) JP5739616B2 (es)
KR (2) KR20150038750A (es)
CN (2) CN105395548A (es)
AR (1) AR065392A1 (es)
AT (1) ATE513547T1 (es)
AU (1) AU2008217301B2 (es)
BR (1) BRPI0806392A8 (es)
CA (1) CA2678975C (es)
CL (1) CL2008000461A1 (es)
CO (1) CO6210814A2 (es)
CY (1) CY1111799T1 (es)
DK (1) DK2120936T3 (es)
EC (1) ECSP099556A (es)
ES (1) ES2367722T3 (es)
HR (1) HRP20110556T1 (es)
IL (1) IL200278A (es)
MX (1) MX2009008825A (es)
MY (1) MY153408A (es)
NZ (1) NZ578473A (es)
PE (1) PE20081789A1 (es)
PL (1) PL2120936T3 (es)
PT (1) PT2120936E (es)
RU (1) RU2484821C2 (es)
SI (1) SI2120936T1 (es)
TW (1) TWI475994B (es)
UA (1) UA98136C2 (es)
UY (1) UY30901A (es)
WO (1) WO2008101591A1 (es)
ZA (1) ZA200904941B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ597920A (en) 2009-08-07 2014-05-30 Generics Uk Ltd Anhydrate of tiotropium bromide
WO2011095800A2 (en) * 2010-02-02 2011-08-11 Generics [Uk] Limited Analytical methods
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
EA201590030A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
EP3589369A4 (en) 2017-01-09 2020-03-18 DAS-MG, Inc. USE AND COMPOSITION FOR TREATING SEVERE MYASTHENIA AND OTHER MYASTHENIC SYNDROMES
WO2019023318A1 (en) * 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
WO2019023175A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
WO2020014072A1 (en) * 2018-07-09 2020-01-16 Gt Biopharma, Inc. Neostigmine pharmaceutical combination for treating myasthenia gravis
EP3939585A4 (en) * 2020-05-20 2022-03-02 Syntekabio, Inc. PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
KR102169476B1 (ko) * 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
EP4469041A4 (en) * 2022-01-28 2026-01-07 Univ Of Montreal ANTICHOLINERGIC COMPOUNDS INTENDED FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN115267024B (zh) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 治疗呼吸系统疾病的药物组合物及其检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Also Published As

Publication number Publication date
PL2120936T3 (pl) 2011-11-30
CA2678975C (en) 2016-11-08
CN105395548A (zh) 2016-03-16
PE20081789A1 (es) 2008-12-27
IL200278A (en) 2015-03-31
ZA200904941B (en) 2011-11-30
KR20090114401A (ko) 2009-11-03
HK1132673A1 (en) 2010-03-05
US20110243924A1 (en) 2011-10-06
RU2484821C2 (ru) 2013-06-20
SI2120936T1 (sl) 2011-10-28
NZ578473A (en) 2011-10-28
CY1111799T1 (el) 2015-10-07
JP5739616B2 (ja) 2015-06-24
MX2009008825A (es) 2009-10-12
TWI475994B (zh) 2015-03-11
JP2010519261A (ja) 2010-06-03
BRPI0806392A8 (pt) 2019-10-01
RU2009135078A (ru) 2011-03-27
ES2367722T3 (es) 2011-11-08
CN101616670A (zh) 2009-12-30
UA98136C2 (ru) 2012-04-25
TW200838520A (en) 2008-10-01
MY153408A (en) 2015-02-13
BRPI0806392A2 (pt) 2011-09-06
AU2008217301B2 (en) 2012-10-04
CA2678975A1 (en) 2008-08-28
AU2008217301A1 (en) 2008-08-28
EP2120936B1 (en) 2011-06-22
KR20150038750A (ko) 2015-04-08
US20150093374A1 (en) 2015-04-02
PT2120936E (pt) 2011-09-06
EP2120936A1 (en) 2009-11-25
CO6210814A2 (es) 2010-10-20
UY30901A (es) 2009-11-10
CL2008000461A1 (es) 2008-08-29
JP2014062114A (ja) 2014-04-10
HRP20110556T1 (hr) 2011-09-30
DK2120936T3 (da) 2011-09-26
ECSP099556A (es) 2009-09-29
ATE513547T1 (de) 2011-07-15
WO2008101591A1 (en) 2008-08-28
IL200278A0 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2016001384A (es) Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
CL2008000607A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor.
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
PL2320878T3 (pl) Monoterpeny do leczenia chorób dróg oddechowych, w szczególności chorób oskrzelowo-płucnych
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
BRPI0822420A2 (pt) Composto, composição farmaceutica, e, métodos para tratar uma doença em uma animal e para tratar um paciente que passa por uma tarepia.
TH0801000702A (th) อะคลิดิเนียมสำหรับใช้โดยการสูดในการบำบัดโรคทางเดินหายใจ

Legal Events

Date Code Title Description
FB Suspension of granting procedure